Orthofix Medical

OFIX

Market cap $536M

Orthofix Medical Inc. (OFIX) Q4 2025 Earnings Call Transcript

Orthofix (OFIX) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.02 per share a year ago.

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2025, provided full-year 2026 financial guidance and updated its three-year financial targets. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights Fourth quarter reported 2025 net sales of $219.

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences: Canaccord Genuity 2026 Musculoskeletal Conference - New Orleans, March 2, 2026, 9:30 am CT TD Cowen 46th Annual Health Care Conference - Boston, March 3, 2026, 11:10 am ET Interested parties can access.

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2025 financial results on Tuesday, February 24, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other location.

Orthofix Medical Inc. ( OFIX ) UBS Global Healthcare Conference 2025 November 11, 2025 1:15 PM EST Company Participants Massimo Calafiore - President, CEO & Director Julie Dewey - Chief Investor Relations & Communications Officer Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division All right. Good afternoon, everyone.

Orthofix Medical Inc. ( OFIX ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Julie Dewey - Chief Investor Relations & Communications Officer Massimo Calafiore - President, CEO & Director Julie Andrews - Chief Financial Officer Conference Call Participants Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Michael Petusky - Barrington Research Associates, Inc., Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today.

Orthofix (OFIX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.07 per share a year ago.

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2025, narrowed its full-year 2025 net sales guidance while maintaining the midpoint, and raised the low end of its adjusted EBITDA guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights Third quarter.

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences: UBS Global Healthcare Conference in Palm Beach Gardens, FL, November 11, 2025, at 1:15 pm Eastern Time Stifel Healthcare Conference in New York, NY, November 12, 2025, at 10:00 am Eastern Time Jefferies.